Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
FDA grants fast review for Bayer/Merck & Co’s heart failure drugThe FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being Share XFDA grants fast review for Bayer/Merck & Co’s heart failure drughttps://pharmaphorum.com/news/fda-grants-fast-review-for-bayer-merck-cos-heart-failure-drug/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
Janssen taps wearable tech in Invokana heart failure trialJanssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world Share XJanssen taps wearable tech in Invokana heart failure trialhttps://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
AZ’s Farxiga gets FDA Fast Track for heart failureThe FDA has fast-tracked AstraZeneca’s Farxiga (dapagliflozin) as a treatment to reduce risk of cardiovascular death, or worsening Share XAZ’s Farxiga gets FDA Fast Track for heart failurehttps://pharmaphorum.com/news/azs-farxiga-gets-fda-fast-track-for-heart-failure/
